UBS Maintains Buy on Medline, Raises Price Target to $49
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $43 to $49.
UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $43 to $49.